Latest Insider Transactions at Longeveron Inc. (LGVN)
This section provides a real-time view of insider transactions for Longeveron Inc. (LGVN). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Longeveron Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Longeveron Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 02
2024
|
Khoso Baluch |
SELL
Open market or private sale
|
Direct |
1,250
-5.0%
|
$2,500
$2.07 P/Share
|
|
Oct 01
2024
|
Mohamed Wa'El Ahmed Hashad Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
13,357
-4.58%
|
$13,357
$1.88 P/Share
|
|
Oct 01
2024
|
Paul T Lehr General Counsel, Secretary |
SELL
Payment of exercise price or tax liability
|
Direct |
990
-0.62%
|
$990
$1.88 P/Share
|
|
Oct 01
2024
|
Nataliya Agafonova Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,316
-3.26%
|
$5,316
$1.88 P/Share
|
|
Oct 01
2024
|
Lisa Locklear Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,316
-3.25%
|
$5,316
$1.88 P/Share
|
|
Aug 15
2024
|
Neil E Hare |
BUY
Grant, award, or other acquisition
|
Direct |
23,500
+44.46%
|
-
|
|
Aug 15
2024
|
Rock Soffer |
BUY
Grant, award, or other acquisition
|
Direct |
23,500
+9.2%
|
-
|
|
Aug 15
2024
|
Ursula Ungaro |
BUY
Grant, award, or other acquisition
|
Direct |
23,500
+49.47%
|
-
|
|
Aug 15
2024
|
Khoso Baluch |
BUY
Grant, award, or other acquisition
|
Direct |
23,500
+37.98%
|
-
|
|
Aug 15
2024
|
Joshua Hare Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
93,766
+11.42%
|
-
|
|
Aug 15
2024
|
Paul T Lehr General Counsel, Secretary |
SELL
Payment of exercise price or tax liability
|
Direct |
31,505
-9.84%
|
$63,010
$2.46 P/Share
|
|
Aug 15
2024
|
Paul T Lehr General Counsel, Secretary |
BUY
Grant, award, or other acquisition
|
Direct |
178,133
+35.74%
|
-
|
|
Aug 15
2024
|
Mohamed Wa'El Ahmed Hashad Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
39,248
-30.28%
|
$78,496
$2.46 P/Share
|
|
Aug 15
2024
|
Mohamed Wa'El Ahmed Hashad Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
311,250
+48.47%
|
-
|
|
Aug 15
2024
|
Lisa Locklear Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
14,035
-7.9%
|
$28,070
$2.46 P/Share
|
|
Aug 15
2024
|
Lisa Locklear Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
174,750
+49.59%
|
-
|
|
Aug 15
2024
|
Nataliya Agafonova Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
14,391
-8.11%
|
$28,782
$2.46 P/Share
|
|
Aug 15
2024
|
Nataliya Agafonova Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
175,750
+49.75%
|
-
|
|
Jul 02
2024
|
Neha J. Motwani |
BUY
Grant, award, or other acquisition
|
Direct |
16,000
+50.0%
|
$16,000
$1.68 P/Share
|
|
Jul 02
2024
|
Roger Joseph Hajjar |
BUY
Grant, award, or other acquisition
|
Direct |
16,000
+50.0%
|
$16,000
$1.68 P/Share
|
|
Jul 01
2024
|
Lisa Locklear Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
357
-10.91%
|
$357
$1.57 P/Share
|
|
Jun 09
2024
|
Khoso Baluch |
SELL
Payment of exercise price or tax liability
|
Direct |
125
-0.83%
|
$125
$1.06 P/Share
|
|
Jun 03
2024
|
Paul T Lehr General Counsel, Secretary |
SELL
Payment of exercise price or tax liability
|
Direct |
325
-0.23%
|
$325
$1.04 P/Share
|
|
May 10
2024
|
Richard N Kender |
BUY
Grant, award, or other acquisition
|
Direct |
16,000
+50.0%
|
$16,000
$1.46 P/Share
|
|
May 02
2024
|
Nataliya Agafonova Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
308
-14.81%
|
$616
$2.83 P/Share
|
|
May 02
2024
|
Lisa Locklear Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
410
-11.13%
|
$820
$2.83 P/Share
|
|
Apr 11
2024
|
Rock Soffer |
BUY
Open market or private purchase
|
Direct |
31,915
+13.27%
|
$63,830
$2.35 P/Share
|
|
Apr 11
2024
|
Mohamed Wa'El Ahmed Hashad Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
10,638
+35.16%
|
$21,276
$2.35 P/Share
|
|
Apr 11
2024
|
Joshua Hare Chief Scientific Officer |
BUY
Open market or private purchase
|
Direct |
42,553
+6.3%
|
$85,106
$2.35 P/Share
|
|
Apr 10
2024
|
Rock Soffer |
BUY
Open market or private purchase
|
Direct |
106,383
+37.59%
|
$212,766
$2.35 P/Share
|
|
Apr 10
2024
|
Joshua Hare Chief Scientific Officer |
BUY
Open market or private purchase
|
Direct |
106,383
+15.26%
|
$212,766
$2.35 P/Share
|
|
Mar 12
2024
|
Mohamed Wa'El Ahmed Hashad Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
32,866
-26.8%
|
$0
$0.54 P/Share
|
|
Mar 12
2024
|
Mohamed Wa'El Ahmed Hashad Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
80,200
+39.54%
|
-
|
|
Jan 10
2024
|
Cathy Ross |
BUY
Open market or private purchase
|
Direct |
5,000
+33.33%
|
$5,000
$1.31 P/Share
|
|
Jan 02
2024
|
Nataliya Agafonova Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,074
-12.88%
|
$3,074
$1.32 P/Share
|
|
Jan 02
2024
|
Paul T Lehr General Counsel, Secretary |
SELL
Payment of exercise price or tax liability
|
Direct |
992
-0.69%
|
$992
$1.32 P/Share
|
|
Jan 02
2024
|
Mohamed Wa'El Ahmed Hashad Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,123
-10.77%
|
$5,123
$1.32 P/Share
|
|
Jan 02
2024
|
Lisa Locklear Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,098
-10.01%
|
$4,098
$1.32 P/Share
|
|
Dec 29
2023
|
Khoso Baluch |
BUY
Open market or private purchase
|
Direct |
8,322
+35.68%
|
$8,322
$1.43 P/Share
|
|
Dec 28
2023
|
Khoso Baluch |
BUY
Open market or private purchase
|
Direct |
1,678
+20.08%
|
$1,678
$1.4 P/Share
|
|
Dec 28
2023
|
Jeffrey Pfeffer |
BUY
Open market or private purchase
|
Direct |
10,000
+40.0%
|
$10,000
$1.35 P/Share
|
|
Oct 02
2023
|
Nataliya Agafonova Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,059
-11.36%
|
$6,118
$2.29 P/Share
|
|
Oct 02
2023
|
Lisa Locklear Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,078
-9.06%
|
$8,156
$2.29 P/Share
|
|
Oct 02
2023
|
Paul T Lehr General Counsel, Secretary |
SELL
Payment of exercise price or tax liability
|
Direct |
815
-0.57%
|
$1,630
$2.29 P/Share
|
|
Sep 21
2023
|
Joshua Hare Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+0.06%
|
$15,000
$3.0 P/Share
|
|
Sep 20
2023
|
Paul T Lehr General Counsel, Secretary |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+1.37%
|
$6,000
$3.0 P/Share
|
|
Sep 12
2023
|
Joshua Hare Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+0.38%
|
$90,000
$3.0 P/Share
|
|
Sep 12
2023
|
Lisa Locklear Chief Financial Officer |
BUY
Exercise of out-of-the-money derivative securities
|
Direct |
5,000
+10.0%
|
$15,000
$3.0 P/Share
|
|
Sep 12
2023
|
Mohamed Wa'El Ahmed Hashad Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+17.37%
|
$30,000
$3.0 P/Share
|
|
Sep 08
2023
|
Rock Soffer |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+4.1%
|
$90,000
$3.0 P/Share
|